Jane Street Group LLC raised its holdings in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 894.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 131,478 shares of the biopharmaceutical company's stock after acquiring an additional 118,262 shares during the period. Jane Street Group LLC owned approximately 0.30% of Abeona Therapeutics worth $732,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in ABEO. Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics in the fourth quarter valued at $118,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at about $341,000. Trexquant Investment LP acquired a new position in shares of Abeona Therapeutics in the 4th quarter worth approximately $382,000. JPMorgan Chase & Co. increased its holdings in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 28,606 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Abeona Therapeutics during the fourth quarter worth $520,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Abeona Therapeutics
In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Alvino sold 8,000 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the sale, the director now directly owns 92,435 shares of the company's stock, valued at approximately $525,030.80. This represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,000 shares of company stock worth $177,700 over the last 90 days. Corporate insiders own 6.90% of the company's stock.
Abeona Therapeutics Stock Down 2.2%
NASDAQ ABEO traded down $0.14 during trading on Friday, reaching $6.03. 133,930 shares of the company's stock were exchanged, compared to its average volume of 1,094,075. The company has a 50 day moving average price of $5.37 and a two-hundred day moving average price of $5.56. The stock has a market cap of $308.22 million, a P/E ratio of -2.24 and a beta of 1.68. Abeona Therapeutics Inc has a 1 year low of $3.93 and a 1 year high of $7.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11. On average, equities research analysts anticipate that Abeona Therapeutics Inc will post -1.16 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on ABEO. Oppenheimer began coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective for the company. Stifel Nicolaus cut their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Finally, HC Wainwright increased their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.50.
Read Our Latest Stock Report on Abeona Therapeutics
About Abeona Therapeutics
(
Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
